In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tristrata lawsuit

This article was originally published in The Rose Sheet

Executive Summary

Valeant Pharmaceutical's motion seeking to overturn a jury verdict finding the company infringed two patents held by Tristrata Corporation and requesting a new trial is rejected by Wilmington, Del. federal court, according to parent company NeoStrata. Court also issues a permanent injunction prohibiting Valeant from the "manufacture, sale and marketing of products covered by the infringed patents." In November, the court ruled that Valeant willfully infringed the two patents, which cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances" (1"The Rose Sheet" Dec. 1, 2003, In Brief). Patent infringement suits are still pending against other firms including Mary Kay cosmetics and BeautiControl...

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts